Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in Elective VATS-Lobectomy for NSCLC
Status:
Recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
Lobectomy is a major, high-risk surgical procedure that in addition to one-lung ventilation
(OLV) exerts a potent surgical stress response. An overwhelming immune cell recruitment may
lead to excessive tissue damage, peripheral organ injury and immunoparesis. The effect of
anesthesia on the immune system is modest, compared to the effects induced by major surgery.
However, to an immunocompromised patient, due to cancer and/or other comorbidities, the
immunosuppressive effects of anesthesia may increase the incidence of post-operative
infections, morbidity, and mortality. Exogenous opioids have been correlated with
immunosuppression, opioid-induced hyperalgesia, and respiratory depression, with deleterious
outcomes. An Opioid-Free Anaesthesia-Analgesia (OFA-A) strategy is based on the
administration of a variety of anaesthetic/analgesic and other pharmacological agents with
different mechanisms of action, including immunomodulating and anti-inflammatory effects. Our
basic hypothesis is that the implementation of a perioperative multimodal OFA-A strategy,
will lead to an attenuated surgical stress response and attenuated immunosuppression,
compared to a conventional Opioid-Based Anaesthesia-Analgesia (OBA-A) strategy. The
aforementioned effects, are presumed to be associated with equal or improved analgesia and
decreased incidence of postoperative infections compared to a perioperative OBA-A technique.